Skip to main content

Table 1 Clinical features of patients with bone and soft tissue sarcoma in AYA

From: Surgical management of sarcoma in adolescent and young adult patients

Patient no.AgeBone or soft tissueSiteHistologyGradeECOG-PSASA-PSChemotherapyTreatmentOp. time (min)Blood loss (mL)MarginLocal recurrenceMetastasisFollow-up periodFinal outcome
117BoneTibiaOsteosarcoma (conventional)High11NECO-95JCT, WR160500R1++43DOD
236BoneTibiaOsteosarcoma (conventional)High01NECO-95JCurettage10810+55NED
339BoneFemurChondrosarcoma grade ILow01Curettage24086066CDF
433BoneFemurChondrosarcoma grade IILow01Curettage12016075CDF
515BoneFemurOsteosarcoma (osteoblastic)High21NECO-95JCT, WR215521R088CDF
636BoneTibiaOsteosarcoma (chondroblastic)High01NECO-95JCT, WR245250R043CDF
727BoneFibulaOsteosarcoma (conventional)High01NECO-95JCT, WR500392R0162CDF
829BoneHumerusOsteosarcoma (conventional)High12NECO-95JCT, WR295571R0+12DOD
935Soft tissueThighLeiomyosarcomaHigh13WR245418R0+45DOD
1032Soft tissueButtockEwingHigh12VAdCA-IECT, WR140615R0+13DOD
1135Soft tissueThighSynovial sarcomaHigh01IA × 3 (post surgery)CT, WR364282R1+20NED
1227Soft tissueAbdomenSynovial sarcomaHigh01IA × 3 (post surgery)CT, WR10210R040CDF
1336Soft tissueUpper extremityLiposarcomaHigh11WR9510R0+54DOD
1426Soft tissueThighMyxoid liposarcomaLow01WR140935R0144CDF
1534Soft tissueThighMyxoid liposarcomaHigh01IA 3 (pre-surgery)/2 (Post surgery)CT, WR145138R1+111NED
1633Soft tissueThighSynovial sarcomaHigh01IA 3 (pre-surgery)/2 (post surgery)CT, WR237235R036CDF
1737Soft tissueButtockMyxoid liposarcomaHigh01IA × 3 (post surgery)CT, WR103196R08CDF
1832Soft tissueGroinMyxoid liposarcomaHigh01IA × 3 (post surgery)WR, RT19150R010CDF
  1. y years, F female, M male, CT chemotherapy, WR wide resection, NECO Neoadjuvant Chemotherapy for Osteosarcoma, IA ifosfamide and doxorubicin, Mo month(s), DOD dead of disease, CDF continuously disease-free, ECOG-PS European Society for Medical Oncology Guidelines Performance Status, ASA-PS American Society of Anesthesiologists-Physical Status, Op. time operation time, VAdCA-IE vincristin, actinomycinD, doxorubicin, cyclophosphamide, ifosfamide, etoposide, NED no evidence of disease